These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22442293)

  • 1. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases.
    Baz Morelli A; Becher D; Koernig S; Silva A; Drane D; Maraskovsky E
    J Med Microbiol; 2012 Jul; 61(Pt 7):935-943. PubMed ID: 22442293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
    Drane D; Gittleson C; Boyle J; Maraskovsky E
    Expert Rev Vaccines; 2007 Oct; 6(5):761-72. PubMed ID: 17931156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ISCOMATRIX adjuvant for antigen delivery.
    Pearse MJ; Drane D
    Adv Drug Deliv Rev; 2005 Jan; 57(3):465-74. PubMed ID: 15560952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
    Maraskovsky E; Schnurr M; Wilson NS; Robson NC; Boyle J; Drane D
    Immunol Cell Biol; 2009 Jul; 87(5):371-6. PubMed ID: 19381160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo.
    Silva A; Mount A; Krstevska K; Pejoski D; Hardy MP; Owczarek C; Scotney P; Maraskovsky E; Baz Morelli A
    J Immunol; 2015 Mar; 194(5):2199-207. PubMed ID: 25646304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.
    Wilson NS; Yang B; Morelli AB; Koernig S; Yang A; Loeser S; Airey D; Provan L; Hass P; Braley H; Couto S; Drane D; Boyle J; Belz GT; Ashkenazi A; Maraskovsky E
    Immunol Cell Biol; 2012 May; 90(5):540-52. PubMed ID: 21894173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.
    Boyle J; Eastman D; Millar C; Camuglia S; Cox J; Pearse M; Good J; Drane D
    Vaccine; 2007 Mar; 25(14):2541-4. PubMed ID: 17240491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.
    Schnurr M; Orban M; Robson NC; Shin A; Braley H; Airey D; Cebon J; Maraskovsky E; Endres S
    J Immunol; 2009 Feb; 182(3):1253-9. PubMed ID: 19155470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses.
    McCluskie MJ; Weeratna RD; Evans DM; Makinen S; Drane D; Davis HL
    Biomed Res Int; 2013; 2013():636847. PubMed ID: 23586050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccine.
    Vujanic A; Snibson KJ; Wee JL; Edwards SJ; Pearse MJ; Scheerlinck JP; Sutton P
    Clin Vaccine Immunol; 2012 Jan; 19(1):79-83. PubMed ID: 22072721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
    Cebon JS; Gore M; Thompson JF; Davis ID; McArthur GA; Walpole E; Smithers M; Cerundolo V; Dunbar PR; MacGregor D; Fisher C; Millward M; Nathan P; Findlay MPN; Hersey P; Evans TRJ; Ottensmeier CH; Marsden J; Dalgleish AG; Corrie PG; Maria M; Brimble M; Williams G; Winkler S; Jackson HM; Endo-Munoz L; Tutuka CSA; Venhaus R; Old LJ; Haack D; Maraskovsky E; Behren A; Chen W
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saponin-adjuvanted particulate vaccines for clinical use.
    Skene CD; Sutton P
    Methods; 2006 Sep; 40(1):53-9. PubMed ID: 16997713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers.
    Drane D; Maraskovsky E; Gibson R; Mitchell S; Barnden M; Moskwa A; Shaw D; Gervase B; Coates S; Houghton M; Basser R
    Hum Vaccin; 2009 Mar; 5(3):151-7. PubMed ID: 19246990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ISCOMs and ISCOMATRIX.
    Sun HX; Xie Y; Ye YP
    Vaccine; 2009 Jul; 27(33):4388-401. PubMed ID: 19450632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract.
    Sanders MT; Deliyannis G; Pearse MJ; McNamara MK; Brown LE
    Vaccine; 2009 Apr; 27(18):2475-82. PubMed ID: 19368789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens.
    Vujanic A; Wee JL; Snibson KJ; Edwards S; Pearse M; Quinn C; Moloney M; Taylor S; Scheerlinck JP; Sutton P
    Vaccine; 2010 Mar; 28(14):2593-7. PubMed ID: 20096391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.
    Pearse MJ; Drane D
    Vaccine; 2004 Jun; 22(19):2391-5. PubMed ID: 15193400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori.
    Skene CD; Doidge C; Sutton P
    Vaccine; 2008 Jul; 26(31):3880-4. PubMed ID: 18547687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer.
    Barr AM; Silva A; Prato S; Belz GT; Maraskovsky E; Baz Morelli A
    Cancer Immunol Immunother; 2020 Oct; 69(10):1959-1972. PubMed ID: 32388678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.